<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00831974</url>
  </required_header>
  <id_info>
    <org_study_id>AB04010</org_study_id>
    <nct_id>NCT00831974</nct_id>
  </id_info>
  <brief_title>Efficacy of AB1010 in Patients With Systemic Indolent Mastocytosis</brief_title>
  <official_title>Phase IIa, Open-label, Randomized Study of Oral AB1010 in Patients With Systemic Indolent Mastocytosis With Handicap and Not Bearing Activating Point Mutations in the Phosphotransferase Domain of c-Kit Such as the Main Mutation Asp-816-Val (D816V)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AB Science</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AB Science</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 12 weeks study aimed at assessing the safety and efficacy of 2 doses of AB1010 in
      patients suffering from indolent systemic mastocytosis with handicap.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Efficacy will be assessed based on:

      Pruritus score Number of flush per day Pollakyuria (on a daily basis) Number of stools per
      day QLQ-C30 score Hamilton Rating Scale for depression
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response on: Pruritus score, Number of flush per day, Pollakyuria (on a daily basis), Number of stools per day, QLQ-C30 score, Hamilton Rating Scale for depression</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AFIRMM score, reduction of organ infiltration,level of tryptase, reduction on bio markers (TNFα, eosinophils, histamine levels), pharmacokinetic profile of AB1010</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Mastocytosis</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>masitinib (AB1010) 6 mg/kg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>masitinib (AB1010) 3 mg/kg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>masitinib (AB1010)</intervention_name>
    <description>3 mg/kg/day</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>masitinib (AB1010)</intervention_name>
    <description>6 mg/kg/day</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with documented Indolent systemic mastocytosis with handicap (ISMwh) having
             at least 2 infiltrated* organs (skin and /or bone-marrow and/or internal organ).

          2. Bone-marrow, or skin or internal biopsy-documented mastocytosis and evaluable disease.

          3. The absence of an activating point mutation in the phosphotransferase domain of c-Kit
             such as D816V c-Kit mutation in at least one of the two infiltrated organs: bone
             marrow and/or skin and/or other tissue.

          4. Handicap defined as at least one of the following handicaps:

               -  a number of flush per day ≥ 1 ,

               -  a pruritus score ≥ 9 ,

               -  a number of stools per day ≥ 4 ,

               -  a Pollakyuria (on a per day basis) ≥ 8 ,

               -  a QLQ-C30 score ≥ 83 ,

               -  a Hamilton rating scale for depression ≥ 12

        Exclusion Criteria:

          1. Performance status &gt; 2 (ECOG).

          2. Inadequate organ function, except if the abnormalities are due to involvement by mast
             cells
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier Lortholary, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Necker, Paris, France</affiliation>
  </overall_official>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 28, 2009</study_first_submitted>
  <study_first_submitted_qc>January 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2009</study_first_posted>
  <last_update_submitted>August 13, 2013</last_update_submitted>
  <last_update_submitted_qc>August 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mastocytosis</keyword>
  <keyword>indolent</keyword>
  <keyword>handicap</keyword>
  <keyword>wild-type</keyword>
  <keyword>systemic</keyword>
  <keyword>not D816V mutated</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mastocytosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

